Skye Bioscience, Inc. (SKYE) stock
Close on Nov 11, 2026Market cap $32.55MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $32.55M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -119.23%
Fundamentals
- Net income
- -$50.49M
- EPS, diluted
- -$1.27
- Free cash flow
- -$38.81M
- Book value per share
- -$0.01
- Diluted shares
- 40M
Trading
- Previous close
- $0.84
- Open
- $0.88
- Day's range
- $0.84 – $0.92
- Volume
- 85,699
- Average volume (20 days)
- 110,937
- Beta (5 years)
- 1.46
- 52-week range
- $0.50 – $12.72
- RSI (14 days)
- 32.1
- Volatility (1 year)
- 98.9%
- Relative volume
- 0.96×
- WACC
- 12.2%
Market cap history
Month-end market cap since 2015, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | SKYE | S&P 500 | Difference | SKYE per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -45.6% | -2.4% | −43.2 pts | ||
| 3 months | -78.8% | -1.2% | −77.6 pts | ||
| Year to date | -84.7% | +12.3% | −97.0 pts | ||
| 1 year | -92.1% | +12.4% | −104.6 pts | ||
| 3 years | -93.2% | +78.8% | −172.1 pts | -59.3% | +21.4% |
| 5 years | -99.3% | +75.2% | −174.5 pts | -63.2% | +11.9% |
| 10 years | -99.9% | +311.1% | −411.0 pts | -49.5% | +15.2% |
Fourteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Skye Bioscience filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Results
- Update
- Update
About Skye Bioscience
Pharmaceutical Preparations
Skye Bioscience, Inc. is a clinical-stage biotechnology company focused on discovering and developing therapies that target G-protein-coupled receptors. The company specializes in modulating cannabinoid receptor 1 to address metabolic conditions, notably obesity and overweight. Its lead therapeutic candidate is nimacimab, a peripherally restricted antibody evaluated both as a monotherapy and in combination with incretin-based treatments. Because its treatments remain in clinical development and are not commercially marketed, the business currently serves participants within clinical trials and seeks collaborations or licensing partnerships with major pharmaceutical organizations.
Company profile, executives and historySkye Bioscience stock: common questions
What is Skye Bioscience's stock price?
SKYE closed at $0.92 on Nov 11, 2026, up 9.54% on the day. Over the past 52 weeks it traded between $0.50 and $12.72.
What is Skye Bioscience's market cap?
Skye Bioscience was worth $32.55M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is SKYE's P/E ratio?
Skye Bioscience lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.27), so it has no meaningful P/E ratio.
Does Skye Bioscience pay a dividend?
No. Skye Bioscience has not paid a cash dividend over the last twelve months.
How has SKYE stock performed over the past year?
Including dividends, SKYE returned -92.1% over the past year, against +12.4% for the S&P 500.
Who are Skye Bioscience's competitors?
Companies most similar to Skye Bioscience by business, industry and size include CRBP, GPCR, SEPN, SYRE, NAMS.
See a number that looks wrong?